Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock Sells 4,500 Shares

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 4,500 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $7.10, for a total transaction of $31,950.00. Following the completion of the sale, the executive vice president now owns 71,365 shares of the company’s stock, valued at $506,691.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ted Yednock also recently made the following trade(s):

• On Thursday, September 5th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.64, for a total transaction of $31,020.00.
• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.95, for a total transaction of $32,725.00.

Annexon Price Performance

Annexon stock opened at $7.03 on Friday. The business has a 50 day moving average price of $6.05 and a two-hundred day moving average price of $5.58. Annexon, Inc. has a 12 month low of $1.57 and a 12 month high of $8.40. The stock has a market cap of $649.66 million, a price-to-earnings ratio of -4.78 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, August 12th. The company reported ($0.23) EPS for the quarter, hitting the consensus estimate of ($0.23). On average, analysts expect that Annexon, Inc. will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Annexon

A number of hedge funds and other institutional investors have recently made changes to their positions in ANNX. Ameritas Investment Partners Inc. raised its position in Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after purchasing an additional 2,949 shares in the last quarter. Sandia Investment Management LP acquired a new position in shares of Annexon in the 2nd quarter worth approximately $49,000. Victory Capital Management Inc. bought a new position in shares of Annexon during the 2nd quarter worth approximately $51,000. Principal Financial Group Inc. acquired a new stake in Annexon in the 2nd quarter valued at $56,000. Finally, Comerica Bank bought a new stake in Annexon in the first quarter valued at $72,000.

Analyst Upgrades and Downgrades

ANNX has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Annexon in a research note on Tuesday, August 13th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research note on Monday, September 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.